Miguel García Deltoro

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

Pedro Cahn, Juan Sierra Madero, José Ramón Arribas et al. · The Lancet · 2018 · 381 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study

Edgar T. Overton, Gary Richmond, Giuliano Rizzardini et al. · The Lancet · 2020 · 364 citations

Pharmacy, Pharmacology, Pharmacotherapy +15

Genetic barrier to resistance for dolutegravir.

Josep M. Llibre, Federico Pulido, Féderico García et al. · PubMed · 2015 · 124 citations

Life Sciences, Infectious Diseases, Pharmacotherapy +17

Genotypic determination of HIV tropism - clinical and methodological recommendations to guide the therapeutic use of CCR5 antagonists.

Eva Poveda, José Alcamı́, Roger Paredes et al. · PubMed · 2010 · 55 citations

Life Sciences, Pharmacology, Pharmacotherapy +13

Efficacy and Freedom: Patient Experiences with the Transition from Daily Oral to Long-Acting Injectable Antiretroviral Therapy to Treat HIV in the Context of Phase 3 Trials

Andrea Mantsios, Miranda Murray, Tahilin Sanchez Karver et al. · AIDS and Behavior · 2020 · 50 citations

Pharmacy, Pharmacotherapy, Clinical Pharmacology +11